SGMO News and Press, Sangamo Therapeutics Inc. From 09/06/21

MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...

Sangamo has transitioned to what they called Wave 2 a couple years ago. Biogen and Novartis have partnered with Sangamo to pursue gene regulation. These partnerships are actively being grown with two executives leaving Novartis to join Sangamo. Research publications indicate IND e...

Sangamo Therapeutics continues to develop their impressive pipeline of both wholly-owned and partnered programs. Sangamo has the potential to receive up to $7B in milestone payments from these pipeline programs. The company's gene therapy for hemophilia A is moving closer to a BLA. Th...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11 th at 2:55pm Eastern Time. The virtual session will be webcast liv...

The following slide deck was published by Sangamo Therapeutics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Sangamo Therapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation

Image source: The Motley Fool. Sangamo Therapeutics, inc (NASDAQ: SGMO) Q2 2021 Earnings Call Aug 5, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Sangamo Therapeutics, inc (SGMO) Q2 2021 Earnings Call Transcript ...

Sangamo Therapeutics, Inc. (SGMO) Q2 2022 Earnings Conference Call August 5, 2021 16:30 ET Company Participants Aron Feingold - Head of Corporate Communications & Investor Relations Officer Sandy Macrae - President & Chief Executive Officer Prathyusha Duraibabu - Chief Financial Offic...

Sangamo Therapeutics (NASDAQ:SGMO): Q2 GAAP EPS of -$0.33 misses by $0.02. Revenue of $27.9M (+29.5% Y/Y) beats by $1.42M. Cash, cash equivalents and marketable securities as of June 30, 2021 were $578.9 million compared to $692.0 million as of December 31, 2020. Guidance for 2021 Reiterated:...

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2021 financial results. “This is an exciting time at Sangamo, as we...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2021 financial results after the market closes on Thursday, August 5, 2021. The press release will be followed by a conference call at ...